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Background: IGFBP-2 binding to RPTP is required for IGF-I-stimulated AKT activation.
Results: IGF-I stimulates PKC recruitment and serine phosphorylation of vimentin leading to vimentin/RPTP association,
RPTP polymerization, and enhanced AKT activation.
Conclusion: Vimentin phosphorylation stimulates vimentin/RPTP association, which mediates RPTP polymerization in
response to IGF-I and IGFBP-2.
Significance: This study demonstrates how these two receptor systems collaborate to obtain optimal IGF-I signal transduction.
Insulin-like growth factor-binding protein-2 (IGFBP-2) func-
tions coordinately with IGF-I to stimulate cellular proliferation
and differentiation. IGFBP-2 binds to receptor tyrosine phos-
phatase  (RPTP), and this binding in conjunction with IGF-I
receptor stimulation induces RPTP polymerization leading to
phosphatase and tensin homolog inactivation, AKT stimula-
tion, and enhanced cell proliferation. To determine the mecha-
nism by which RPTP polymerization is regulated, we analyzed
the protein(s) that associated with RPTP in response to IGF-I
and IGFBP-2 in vascular smooth muscle cells. Proteomic exper-
iments revealed that IGF-I stimulated the intermediate filament
protein vimentin to bind to RPTP, and knockdown of vimentin
resulted in failure of IGFBP-2 and IGF-I to stimulate RPTP
polymerization. Knockdown of IGFBP-2 or inhibition of IGF-IR
tyrosine kinase disrupted vimentin/RPTP association. Vimen-
tin binding to RPTP was mediated through vimentin serine
phosphorylation. The serine threonine kinase PKC was
recruited to vimentin in response to IGF-I and inhibition of
PKC activation blocked these signaling events. A cell-permea-
ble peptide that contained the vimentin phosphorylation site
disrupted vimentin/RPTP association, and IGF-I stimulated
RPTP polymerization and AKT activation. Integrin-linked
kinase recruited PKC to SHPS-1-associated vimentin in
response to IGF-I and inhibition of integrin-linked kinase/PKC
association reduced vimentin serine phosphorylation. PKC
stimulation of vimentin phosphorylation required high glucose
and vimentin/RPTP-association occurred only during hyper-
glycemia. Disruption of vimetin/RPTP in diabetic mice inhib-
ited RPTP polymerization, vimentin serine phosphorylation,
and AKT activation in response to IGF-I, whereas nondiabetic
miceshowednodifference.Theinductionofvimentinphosphor-
ylation is important for IGFBP-2-mediated enhancement of
IGF-I-stimulated proliferation during hyperglycemia, and it
coordinates signaling between these two receptor-linked signal-
ing systems.
The insulin-like growth factor-binding proteins were ini-
tially proposed as inert carriers of IGF-I whose primary func-
tion was to limit IGF-I access to receptors (1). Subsequent stud-
ies demonstrated that IGFBP3 modulated IGF-I cellular actions
and that they had effects that were believed to be IGF-I-inde-
pendent (2– 4). Although several empiric observations have
been published, the cell surface receptors that mediate these
events and the signaling components that are required have
rarely been characterized (5–7). Our recent studies demon-
strated that IGFBP-2 significantly enhanced the ability of IGF-I
to stimulate vascular smooth muscle cell (VSMC) proliferation
and preosteoblast differentiation (8, 9). We further determined
that IGFBP-2 binding to the specific cell surface receptor
RPTP was required to mediate these effects (9). Knockdown of
RPTP resulted in an inability of IGFBP-2 to stimulate these
responses. Following RPTP polymerization, its phosphatase
activity is inhibited. Utilization of a substrate-trapping mutant
showed that the primary target of RPTP was PTEN and that
RPTP polymerization was associated with enhanced PTEN
tyrosine phosphorylation (9). PTEN tyrosine phosphorylation
inhibited its activity leading to enhanced AKT activation.
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exposure to IGFBP-2 and IGF-I resulted in enhanced VSMC
migration. IGFBP-2 binding to RPTP is also required for IGF-I
to stimulate preosteoblast differentiation (10), and IGFBP-2
knockdown results in attenuation of osteoclast differentiation
(11). Those studies showed that in addition to IGFBP-2 binding
to RPTP, IGF-I receptor activation was required, and inhibi-
tion of the IGF-I receptor tyrosine kinase inhibited RPTP poly-
merization. Because activation of the IGF-I receptor as well as
IGFBP-2 binding to RPTP was required to induce RPTP poly-
merization, we wished to determine the mechanism by which
IGF-I functioned to stimulate this interaction. These studies
were undertaken to determine post-receptor signaling events
that led RPTP polymerization.
EXPERIMENTAL PROCEDURES
Human IGF-I was a gift from Genentech (San Francisco,
CA). Immobilon-P membranes, an ILK inhibitor (Cpd 22), a
myristoylated form of cell-permeable PKC pseudosubstrate
inhibitor (catalog no. 539624) (12), and protein A- and G-aga-
rose were purchased from EMD-Millipore (Billerica, MA). Dul-
becco’s modified medium (DMEM) containing 25 mM glucose,
streptomycin, and penicillin were purchased from Life Tech-
nologies, Inc. PQ401 was purchased from Tocris Bioscience
(Ellisville, MO). Antibodies against PTEN and phospho-
AKT(S473) were from Cell Signaling Technology Inc. (Beverly,
MA). The anti-phosphotyrosine (pY99), ILK, and vimentin
antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). An anti-phosphoserine (Ser(P)) antibody
was purchased from Abcam (Cambridge, MA). An anti-RPTP
monoclonal antibody was purchased from BD Biosciences.
SHPS-1 polyclonal antiserum was prepared as described previ-
ously (13). The IGFBP-2 antibody was prepared as described
previously (8). The horseradish peroxidase-conjugated mouse
anti-rabbit, goat anti-mouse, and mouse anti-rabbit light chain-
specific antibodies were purchased from Jackson Immuno-
Research (West Grove, PA). All other reagents were pur-
chased from Sigma unless otherwise stated. A synthetic peptide
containing the cell permeability sequence of the protein trans-
duction domain and the head domain sequence (underlined)
from vimentin (YARAAARQARAR-SVSSSSYRRMF), hereaf-
ter referred as a disrupting peptide, and a peptide containing
YARAAARQARAR-SVASAAYRRMF, wherein three serines
were substituted with alanine (underlined), serving as a control
peptide, were synthesized by the Protein Chemistry Core Facil-
ity at the University of North Carolina at Chapel Hill. Purity and
the sequence were confirmed by mass spectrometry.
Cell Culture—The VSMC were isolated from the aortic
explants obtained from 3-week-old pigs and were maintained
as described previously (14). Cells were maintained in DMEM
high glucose (25 mM) or DMEM with normal glucose (5 mM)
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT), 100
g/ml streptomycin, and 100 units/ml penicillin. In some
experiments, 20 mM glucose was added to cells that had been
exposed to normal glucose for different times prior to IGF addi-
tion. The cultures were used between passages 5 and 14.
Identification of RPTP Interaction Proteins by Tandem
Mass Spectrometry (MALDI-TOF/MS)—VSMCs with or with-
out IGF-I (50 ng/ml) treatment were lysed in the modified
radioimmunoprecipitation assay (RIPA) buffer. Cell lysates (3
mg) were precleared with protein A/G-agarose for 30 min to
eliminate nonspecific protein interactions and then incubated
with an anti-RPTP antibody (6 g) and protein A/G-agarose
at 4 °C with gentle agitation for 3 h. The immunocomplexes
were separated on a 4 –20% gradient SDS-PAGE. The gel was
stained with colloidal Blue G-250 (Thermo Fisher Scientific,
Rockford, IL). The protein band that was increased in response
to IGF-I was excised from the stained gel, destained with 200
mM ammonium bicarbonate (pH 8.0), 40% acetonitrile, twice at
37 °C for 30 min. The gel was exposed for 10 min to 100 mM
ammonium bicarbonate, cut into small pieces, then dehydrated
with 100% acetonitrile, and vacuum-dried. In-gel digestion was
performed by adding 30 l of modified porcine trypsin solution
(Promega, Madison, WI) at 20 ng/l in 50 mM ammonium
bicarbonate following by a 14-h incubation at room tempera-
ture. Peptides were extracted with 50% (v/v) acetonitrile and
0.1% trifluoroacetic acid twice at 37 °C for 30 min, and the solu-
tion was completely dried in speed vacuum prior to MALDI-
MS analysis conducted by the Proteomics Core Facility at the
University of North Carolina at Chapel Hill.
Generation and Purification of Wild Type IGFBP-2 and an
IGFBP-2 Mutant—Wild type mouse IGFBP-2 and heparin
binding domain mutated IGFBP-2 (MT1) were generated and
purified following the procedure described previously (9).
Establishment of VSMCs Expressing Wild Type SHPS-1 and
Cytoplasmic Domain Truncated SHPS-1—VSMCs expressing
wild type SHPS-1 (SHPS-1/WT) and cytoplasmic domain trun-
cated SHPS-1 (SHPS-1/-CD) were prepared as described previ-
ously (15).
Establishment of VSMCs Expressing IGFBP-2 shRNA and
Control shRNA—Based on Invitrogen website design tools,
sequences containing 21 oligonucleotides (GG AGT TCT GAC
ATG CGT ATT T) were used to construct a short hairpin RNA
(shRNA) template plasmid in order to knock down IGFBP-2.
Two-nucleotide substitutions (underlined GGAGTTCTGT-
GATGCGTATT) were inserted as a control shRNA. VSMCs
expressing shRNA targeting IGFBP-2 and control shRNA were
established following the procedure described previously (9).
Transient Transfection with siRNA Targeting Vimentin—
siRNA targeting vimentin (sc-29523) and a control siRNA (sc-
37007) were purchased from Santa Cruz Biotechnology, Inc.
VSMCs were transfected using a concentration of 40 nM and
the PepMute Plus reagent (SignaGen Laboratories) following
the manufacturer’s instructions. The experiments were initi-
ated 72 h after transfection.
Immunoprecipitation and Immunoblotting—The immuno-
precipitation and immunoblotting procedures were performed
as described previously (9). Immunoprecipitation was per-
formed by incubating 0.5 mg of cell lysate protein with 1 g of
each of the following antibodies: anti-vimentin, ILK, pY99, and
Ser(P) at 4 °C overnight. Immunoblotting was performed using
a dilution of 1:1000 for anti-pAKT(S473), PTEN, vimentin, and
-actin antibodies, a dilution of 1:500 for anti-RPTP antibody,
and a dilution of 1:2000 for anti-IGFBP-2 antibody. The pro-
teins were visualized using enhanced chemiluminescence
(Thermo Fisher Scientific, Rockford, IL).
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Chemical Cross-linking—The chemical cross-linking proce-
dures were performed as described previously (9). Briefly, cells
were washed three times with PBS and then incubated with 2
mg/ml bis[sulfosuccinimidyl]suberate, BS3 (Thermo Fisher
Scientific, Rockford, IL) in PBS for 1 h on ice. Cross-linking was
terminated by adding 50 mM Tris for 15 min. The cells were
lysed, and the lysate was separated onto a 6% SDS-polyacryl-
amide gel.
Induction of Hyperglycemia in Mice and Preparation of Aor-
tas for Analysis—All mouse experiments were approved by the
Institutional Animal Care and Use Committees of the Univer-
sity of North Carolina at Chapel Hill. Hyperglycemia was
induced in C57/B6 mice (Taconic, Hudson, NY) using the low
dose streptozotocin (16). The mean weight and serum glucose
concentration was 27.1  0.6 g and 120.6  22.6 mg/dl before
streptozotocin injection. One week after injection, mean serum
glucose concentration was 311.6  21.4 mg/dl. The mice were
maintained for another 2 weeks before any treatment. The
mean weight and serum glucose concentration was 26.0  0.9 g
and 430.3  59.2 mg/dl before sacrifice. There were 12 mice per
treatment group. The disrupting peptide (4 mg/kg) or control
peptide (4 mg/kg) was administered intraperitoneally twice (24
and 1 h before sacrifice) and IGF-I (1 mg/kg) or PBS was admin-
istered intraperitoneally 15 min before sacrifice. The aortic
extracts were prepared following the procedure described pre-
viously (17). The protein concentration of aortic extracts was
measured using a BCA assay (Thermo Scientific). Equal
amounts of protein were used for each analysis.
Statistical Analysis—The results that are shown in all exper-
iments are representative of at least three independent experi-
ments and expressed as the mean  S.D. The Student’s t test
was used to compare differences between two treatments for in
vitro experiments. The Bonferroni correction was used when
multiple variables were compared. One-way analysis of vari-
ance was applied for all data obtained from in vivo studies. In
addition, repeated measures-analysis of variance was used
where appropriate. p  0.05 was considered statistically
significant.
RESULTS
To determine whether a specific protein(s) associated with
RPTP in response to IGF-I stimulation, we exposed VSMCs to
IGF-I for 10 min in the presence of IGFBP-2 and then immu-
noprecipitated RPTP. The proteins that coimmunoprecipi-
tated were separated by SDS-PAGE, and Colloidal Blue staining
showed a major increase in a 58,000-kDa band in response
IGF-I stimulation (Fig. 1A). Amino acid sequence analysis
revealed that the band was the intermediate filament protein
vimentin. That vimentin bound to RPTP in response to IGF-I
was confirmed using immunoprecipitation (3.2  0.6-fold
increase) (Fig. 1B). To determine whether vimentin binding to
RPTP mediated RPTP polymerization, siRNA was utilized to
knock down vimentin, which resulted in 86  5% inhibition of
vimentin synthesis (p  0.001) (Fig. 2A). Transient knockdown
of vimentin did not result in a change in cell morphology, cyto-
skeletal structure, or increased cell death (data not shown).
Exposure of cells expressing a control siRNA to IGF-I plus
IGFBP-2 resulted in a 7.0  0.4-fold greater stimulation of
vimentin binding to RPTP compared with cells expressing the
vimentin siRNA (p  0.001) (Fig. 2B). To assess the functional
significance of loss of RPTP/vimentin association, we deter-
mined the effect of IGF-I plus IGFBP-2 on RPTP polymeriza-
tion. As shown in Fig. 2C, cells expressing vimentin siRNA had
complete attenuation of RPTP polymerization indicating that
vimentin binding to RPTP was absolutely required. To assess
the functional significance of loss of RPTP polymerization, we
analyzed PTEN tyrosine phosphorylation because RPTP spe-
cifically dephosphorylates this substrate (9). As shown in Fig.
2D, IGF-I stimulated a 4.3  0.3-fold increase in PTEN tyrosine
phosphorylation, whereas vimentin knockdown resulted in
near complete loss of the IGF-I/IGFBP-2-stimulated response
(e.g. 1.4  0.2-fold increase) (p  0.01 compared with control).
IGF-I-stimulated a 7.2  1.4-fold increase (p  0.001) in AKT
phosphorylation in control cells, and this response was signifi-
cantly attenuated in cells treated with vimentin siRNA (p 
0.01) (Fig. 2E). Therefore, vimentin association with RPTP is
required for IGF-I-stimulated RPTP polymerization and opti-
mum enhancement of AKT activation.
FIGURE 1. IGF-I stimulates vimentin/RPTP interaction in VSMCs during
hyperglycemia. VSMCs were cultured in DMEM containing high glucose (25
mM) plus 10% FBS and then serum-deprived for 16 h before stimulation with-
out () or with () IGF-I (50 ng/ml) for 10 min. A, protein band (arrow) that
was increased in response to IGF-I was analyzed by MALDI-TOF/MS as
described under “Experimental Procedures.” B, cell lysates were immunopre-
cipitated (IP) with an anti-vimentin antibody and immunoblotted with an
anti-RPTP antibody. To control for loading, the blot was stripped and rep-
robed with an anti-vimentin antibody. Each bar is the ratio of the mean value
of the scanning units for vimentin-associated RPTP divided by total vimen-
tin. Ctrl, control. **, p  0.01 indicates significant differences between two
treatments.
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To determine the relative importance of IGFBP-2 binding to
RPTP and whether IGF-I activation of IGF-IR is required for
stimulation of vimentin binding to RPTP, we used cells
expressing an IGFBP-2 shRNA that had been shown to have
impaired RPTP polymerization (9). Cells expressing the
IGFBP-2 shRNA had a 93  8% decrease in IGFBP-2 secretion
and showed no vimentin/RPTP binding (Fig. 3A). Exposure of
the knockdown cells to IGFBP-2 and IGF-I rescued vimentin/
RPTP association (5.4  0.7-fold increase compared with
6.8  0.2-fold in control cells). IGF-I receptor activation was
also required for vimentin to bind to RPTP, because in the
presence of an IGF-IR tyrosine kinase inhibitor, PQ401, there
was a 72  10% (p  0.01) reduction in stimulation of vimentin/
RPTP association (Fig. 3B). To determine the region of
IGFBP-2 that was interacting with RPTP to facilitate vimentin
binding, we utilized cells expressing an IGFBP-2 mutant (MT-
1), which had been shown previously to have attenuated RPTP
binding. This mutant has no reduction in its affinity for IGF-I.
Stimulation of the cultures with IGF-I and the mutant form of
IGFBP-2 resulted in significant attenuation of stimulation
RPTP/vimentin association (79  6% reduction, p  0.001)
(Fig. 3C).
To determine the mechanism by which IGF-I receptor acti-
vation stimulated vimentin/RPTP association, we analyzed
theroleofvimentinserinephosphorylationbecauseserinephos-
phorylation of the vimentin head domain has been shown to
FIGURE 2. Vimentin is required for IGF-I-stimulated RPTP polymerization, PTEN tyrosine phosphorylation, and AKT activation. VSMCs treated with the
siRNA targeting vimentin (vimentin Si) and a control siRNA (Ctrl Si) were serum-deprived for 16 h and then incubated without () or with () IGF-I (50 ng/ml)
for 10 min. A, cell lysates were immunoblotted (IB) with an anti-vimentin antibody. To control for loading, the blot was stripped and reprobed with an
anti--actin antibody. B, cell lysates were immunoprecipitated (IP) with an anti-vimentin antibody and immunoblotted with an anti-RPTP antibody. To control
for loading, the same amount of lysate was immunoblotted with an anti-RPTP antibody. Each bar is the ratio of the mean value of the scanning units for
vimentin-associated RPTP divided by total RPTP. C, before lysis, cells were exposed to the noncell-permeable cross-linker bis[sulfosuccinimidyl]suberate as
described under “Experimental Procedures.” The cell lysates were immunoblotted with an anti-RPTP antibody. To control for loading, the same amount of
lysate was immunoblotted with an anti--actin antibody. #, monomer; ##, dimer. D, cell lysates were immunoprecipitated with an anti-pY99 antibody and
immunoblotted with an anti-PTEN antibody. The control lysate was immunoblotted with an anti-PTEN antibody. Each bar is the ratio of the mean value of the
scanning units for pPTEN divided by total PTEN. E, cell lysates were immunoblotted with an anti-pAKT(S473) antibody. The blot was stripped and reprobed with
an anti--actin antibody. Each bar is the ratio of the mean value of the scanning units for pAKT divided by -actin. *, p  0.05, and **, p  0.01, indicate
significant differences between two treatments.
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mediate protein/protein interactions (18). Following IGF-I
stimulation, there was a 5.1  0.4-fold increase in serine phos-
phorylation of vimentin (Fig. 4A). The IGF-IR tyrosine kinase
inhibitor significantly inhibited IGF-I-stimulated vimentin ser-
ine phosphorylation (1.7  0.3-fold increase) (82  12% reduc-
tion compared with control, p  0.001) (Fig. 4A). In contrast,
when cells expressing IGFBP-2 shRNA were analyzed, there
was no inhibition of IGF-I-stimulated vimentin phosphoryla-
tion (e.g. an 3.6  0.6-fold increase in control cells and an 3.3 
0.9-fold increase in IGFBP-2 knockdown cells) (Fig. 4B). The
vimentin head domain sequence contains 16 known serine
phosphorylationsites (18).Toidentify thekinasethatphosphor-
ylated vimentin, we prepared cell-permeable peptides that con-
tained sequence motifs that had been shown to be phosphory-
lated by specific kinases that were known to phosphorylate
vimentin, and we then screened them for their ability to disrupt
RPTP/vimentin association. The response to a cell-permeable
peptide that contained the consensus sequence of a known
PKC phosphorylation site located between residues 2 and 11
in the vimentin N terminus was compared to a control peptide
in which three of the serines in this sequence had been substi-
tuted with alanine. The native peptide completely inhibited
RPTP/vimentin association in response to IGF-I, whereas the
control peptide had no effect (Fig. 5A). To assess the functional
consequence of inhibiting vimentin/RPTP association, we
repeated the experiment and then assessed the effect on RPTP
polymerization. As shown in Fig. 5B, this was completely inhib-
ited, and the ability of IGF-I/IGFBP-2 to stimulate PTEN tyro-
sine phosphorylation was also significantly decreased (Fig. 5C).
Subsequent analysis of IGF-I-stimulated AKT activation
revealed the predicted increase and a significant reduction (e.g.
76  8% decrease, p  0.01) in the degree of stimulation follow-
ing exposure to the vimentin/RPTP-disrupting peptide (Fig.
5D). Exposure to the disrupting peptide had no effect on vimen-
tin phosphorylation (Fig. 5E), thereby excluding the possibility
that it functioned to inhibit kinase activity.
The results shown in Fig. 5 suggested PKC is the kinase that
phosphorylates vimentin in response to IGF-I. Our prior stud-
ies have shown that in this cell type exposure to hyperglycemia
and IGF-I specifically activates PKC and that PKC is required
for optimal IGF-I stimulation of downstream signaling (17).
Based on that result, we stimulated cultures with IGF-I and
then examined vimentin serine phosphorylation in the pres-
ence or absence of a cell-permeable peptide containing the
sequence of a PKC pseudosubstrate peptide inhibitor (12).
IGF-I-stimulated vimentin serine phosphorylation was signifi-
cantly attenuated in the cultures exposed to the PKC inhibitor
(Fig. 6A), leading to impaired vimentin/RPTP association
FIGURE 3. IGF-I-stimulated vimentin/RPTP association requires IGF-I receptor activation and the presence of IGFBP-2. A and C, VSMCs were transduced
with control (Ctrl si) or IGFBP-2 shRNA (IGFBP-2 Si) template plasmids, and conditioned medium was analyzed for IGFBP-2. Cell lysates were immunoblotted (IB)
with an anti--actin antibody as a loading control (A). Cells were serum-deprived for 16 h before incubation without () or with () IGF-I (50 ng/ml) for 10 min.
VSMC expressing IGFBP-2 shRNA were incubated with or without wild type IGFBP-2 (200 ng/ml) (A) or an IGFBP-2 mutant (MT1) (200 ng/ml) (C) for 2 h prior to
IGF-I stimulation. B, VSMCs were serum-deprived for 16 h and then incubated with the IGF-I receptor tyrosine kinase inhibitor, PQ401, or vehicle for 1 h prior to
IGF-I (50 ng/ml) stimulation () or no stimulation () for 10 min. A–C, cell lysates were immunoprecipitated (IP) with an anti-vimentin antibody and immuno-
blotted with an anti-RPTP antibody. The blot was stripped and reprobed with an anti-vimentin antibody. Each bar is the ratio of the scanning units for
vimentin-associated RPTP divided by vimentin. **, p  0.01 indicates significant differences.
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(Fig. 6B). In contrast, when cells were maintained in 5 mM glu-
cose, there was no increase of vimentin serine phosphorylation
and no vimentin/RPTP association (Fig. 6, C and D). To con-
firm that the peptide was inhibiting vimentin/RPTP associa-
tion by inhibiting vimentin phosphorylation and not by inhib-
iting vimentin binding to PKC, we immunoprecipitated
vimentin and immunoblotted for PKC following IGF-I stimu-
lation. IGF-I stimulated PKC/vimentin association, and the
pseudosubstrate inhibitor had no effect on this protein/protein
interaction (Fig. 6E). We subsequently determined that expo-
sure to the pseudosubstrate inhibitor completely inhibited
RPTP polymerization (Fig. 6F) indicating that recruitment of
this kinase to vimentin and its subsequent phosphorylation is
critical for PKC stimulation of vimentin serine phosphoryla-
tion and RPTP polymerization.
In VSMC exposed to hyperglycemia, IRS-1 is down-regu-
lated, and IGF-I receptor-linked signaling occurs through
assembly of a signaling complex on the plasma membrane-as-
sociated scaffold, SHPS-1. SHPS-1 is tyrosine-phosphorylated
in response to IGF-I receptor stimulation, and inhibition of
formation of this signaling complex on the SHPS-1 scaffold
results in major attenuation of AKT activation (19). Therefore,
to identify the proximal signaling components that were
required for PKC recruitment to vimentin, we investigated the
role of the SHPS-1 signaling complex. Our prior proteomic
screening studies had shown that ILK is preferentially recruited
to SHPS-1 in response to IGF-I stimulation (15). Based on that
result, we determined whether PKC was recruited to ILK fol-
lowing IGF-I stimulation. As shown in Fig. 7A, following IGF-I
stimulation PKC was recruited to ILK, and this was inhibited
by an ILK inhibitor (72  8% decrease, p  0.01). More impor-
tantly, exposure to the inhibitor also disrupted PKC recruit-
ment to vimentin (Fig. 7B), and IGF-I stimulated vimentin ser-
ine phosphorylation (77  7% reduction with 5 M, compared
with control, p  0.01) (Fig. 7C). This was associated with the
failure to recruit vimentin to RPTP (Fig. 7D) and loss of IGF-
I-stimulated AKT phosphorylation (Fig. 7E). To determine
whether ILK was facilitating PKC/vimentin association
through recruitment of PKC to SHPS-1, we utilized cells
expressing an SHPS-1 cytoplasmic domain-truncated mutant
that did not bind ILK (15). Expression of this SHPS-1 mutant
resulted in failure to recruit PKC to vimentin (Fig. 7F), and this
was associated with inhibition of IGF-I-stimulated vimentin
phosphorylation (Fig. 7G). Subsequently, we determined that in
the absence of the SHPS-1 cytoplasmic domain, PKC was not
recruited to SHPS-1 (Fig. 7H). This confirmed that the SHPS-1
scaffold was necessary for PKC/vimentin association. This failure
to recruit PKC to SHPS-1 resulted in nearly complete loss of IGF-
I-stimulated vimentin binding to RPTP (Fig. 7I).
To determine the significance of these signaling events in
vivo, mice were made diabetic and then exposed to the peptide
that inhibited vimentin/RPTP association. Analysis of the
aortas following the injection of a biotinylated form of the pep-
tide showed that it was taken up by the aortas in 1 h (data not
shown). Following injection of IGF-I, there was marked stimu-
lation of RPTP/vimentin binding, and this was significantly
inhibited in the presence of disrupting the peptide (Fig. 8A). In
contrast, the control peptide had no effect (Fig. 8A). IGF-I stim-
ulated a 4.3  0.7-fold increase in vimentin serine phosphory-
lation that was attenuated with exposure of the mice to the
PCK inhibitor (Fig. 8B). In contrast, nondiabetic mice showed
no increase in vimentin serine phosphorylation (Fig. 8C). The
disrupting peptide also inhibited IGF-I-stimulated PTEN tyro-
sine phosphorylation (Fig. 8D) and AKT activation (a 78  7%
reduction compared with control, p  0.01) (Fig. 8E). We have
reported that these signaling events are attenuated in nondia-
FIGURE 4. IGF-I-stimulated vimentin serine phosphorylation requires IGF-I receptor activation but not IGFBP-2 stimulation. A, VSMCs were serum-
deprived for 16 h and then incubated with the IGF-I receptor tyrosine kinase inhibitor, PQ401, or vehicle for 1 h prior to IGF-I (50 ng/ml) stimulation () or no
stimulation () for 10 min. B, VSMCs expressing the shRNA targeting control (Ctrl Si) and IGFBP-2 (IGFBP-2 Si) were serum-deprived for 16 h before stimulation
without () or with () IGF-I (50 ng/ml) for 10 min. A and B, cell lysates were immunoprecipitated (IP) with an anti-Ser(P) (pSer) antibody and immunoblotted
(IB) with an anti-vimentin antibody. The same amount of lysate was immunoblotted with an anti--actin antibody. Each bar is the ratio of the scanning units for
serine phosphate vimentin divided by -actin. ***, p  0.001 indicates significant differences between two treatments. P, NS indicates no significant difference.
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betic mice (9, 20). Therefore, this interconnected series of sig-
naling events that had been delineated in smooth muscle cells
in culture could be reproduced in intact aorta in diabetic mice.
DISCUSSION
Our prior studies showed that IGFBP-2 stimulates RPTP
polymerization leading to inhibition of its tyrosine phosphatase
activity and enhanced tyrosine phosphorylation of PTEN, its
primary target in vascular smooth muscle cells and preosteo-
blasts (9, 10). This increase in PTEN tyrosine phosphorylation
led to reduced PTEN enzymatic activity resulting in enhanced
AKT activation and stimulation of vascular smooth muscle
migration or osteoblast differentiation responses to IGF-I
(9 –11). Although binding of IGFBP-2 to RPTP through its
FIGURE 5. Disruption of vimentin/RPTP association impaired IGF-I-stimulated RPTP polymerization, PTEN tyrosine phosphorylation, and AKT
activation. VSMCs were serum-deprived for 16 h and then incubated with a control (Ctrl) peptide (CP) or a peptide that disrupted vimentin/RPTP (AP) for 2 h
prior to IGF-I (50 ng/ml) stimulation () or no stimulation () for 10 min. A, cell lysates were immunoprecipitated (IP) with an anti-vimentin antibody and
immunoblotted (IB) with an anti-RPTP antibody. To control for loading, the blot was stripped and reprobed with an anti-vimentin antibody. B, before lysis,
cells were exposed to the noncell-permeable cross-linker bis[sulfosuccinimidyl]suberate as described under “Experimental Procedures.” The cell lysates were
immunoblotted with an anti-RPTP antibody. The same amount of lysate was immunoblotted with an anti--actin antibody. ##, dimer. C, cell lysates were
immunoprecipitated with an anti-pY99 antibody and immunoblotted with an anti-PTEN antibody. The same amount of lysate was immunoblotted with an
anti-PTEN antibody. D, cell lysates were immunoblotted with an anti-pAKT(S473) antibody. The blot was stripped and reprobed with an anti--actin antibody.
E, cell lysates were immunoprecipitated with an anti-Ser(P) antibody and immunoblotted with an anti-vimentin antibody. The value of each bar is the ratio of
the scanning units for vimentin-associated RPTP divided by vimentin (A), RPTP divided by -actin (B), pPTEN divided by PTEN (C), pAKT divided by -actin
(D), and serine phosphorylated vimentin divided by vimentin (E). **, p  0.01, and ***, p  0.001, indicate significant differences between two treatments. P, NS
indicates no significant difference.
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FIGURE 6. PKC mediates IGF-I-stimulated vimentin serine phosphorylation. VSMCs were serum-deprived for 16 h and then incubated without or
with a PKC inhibitor (10 M) for 1 h prior to IGF-I (50 ng/ml) stimulation () or no stimulation () for 10 min. A, cell lysates were immunoprecipitated
(IP) with an anti-Ser(P) (pSer) antibody and immunoblotted (IB) with an anti-vimentin antibody. Loading controls were immunoblotted with an anti-
vimentin antibody. B, cell lysates were immunoprecipitated with an anti-vimentin antibody and immunoblotted with an anti-RPTP antibody. The blot
was stripped and reprobed with an anti-vimentin antibody. C and D, VSMCs cultured in normal glucose (5 mM, NG) or high glucose (25 mM, HG) were
serum-deprived for 16 h before IGF-I stimulation for 10 min with () or without stimulation (). Cell lysates were immunoprecipitated with an
anti-Ser(P) antibody and immunoblotted with an anti-vimentin (C) or with an anti-vimentin antibody and immunoblotted with an anti-RPTP antibody
(D). Loading controls were immunoblotted with an anti-vimentin antibody. E, cell lysates were immunoprecipitated with an anti-vimentin antibody and
immunoblotted with an anti-PKC antibody. The same amount of lysate was immunoblotted with an anti-PKC antibody. F, before lysis, cells were
exposed to the noncell-permeable cross-linker bis[sulfosuccinimidyl]suberate as described under “Experimental Procedures.” The cell lysates were
immunoblotted with an anti-RPTP antibody or an anti--actin antibody. ##, dimer. The mean scanning units for serine-phosphorylated vimentin
divided by vimentin (A), vimentin-associated RPTP divided by vimentin (B), serine-phosphorylated vimentin divided by vimentin (C), vimentin-
associated RPTP divided by vimentin (D), vimentin-associated PKC divided by PKC (E), and RPTP divided by -actin (F). **, p  0.01, and ***, p 
0.001, indicate significant differences between two treatments. P, NS indicates no significant difference.
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heparin binding domain was required for RPTP polymeriza-
tion, concomitant activation of the IGF-I receptor was also
required. Therefore, these studies were undertaken to deter-
mine the mechanism by which IGF-I enhanced the ability of
IGFBP-2 to stimulate RPTP polymerization. The results
definitively show that IGF-I receptor activation stimulates
vimentin binding to RPTP and that this is absolutely required
for RPTP polymerization. Disruption of vimentin binding
either by vimentin knockdown or the utilization of a cell-per-
meable peptide that inhibited the interaction of the two pro-
FIGURE 7. ILK is recruited to SHPS-1 and mediates IGF-I-stimulated vimentin/PKC interaction. A–E, VSMCs were serum-deprived for 16 h and then
incubated without or with an ILK inhibitor (5 M, or indicated concentrations) for 1 h prior to IGF-I (50 ng/ml) stimulation () or no stimulation () for 10 min.
Cell lysates were immunoprecipitated (IP) with an anti-ILK (A) or anti-vimentin (B and D) or anti-Ser(P) (pSer) (C) antibody and immunoblotted with an anti-PKC
(A and B) or anti-vimentin (C) or anti-RPTP (D) antibody. To control for loading, the same amount of lysate was immunoblotted with an anti-PKC (A and B) or
anti-vimentin (C) or anti-RPTP (D) antibody. E, cell lysates were immunoblotted with an anti-pAKT(S473) antibody. The blot was reprobed with an anti--actin
antibody. F–I, VSMCs expressing wild type SHPS-1 (SHPS-1 WT) or cytoplasmic domain-truncated SHPS-1 (SHPS-1 CD) were serum-deprived for 16 h before
stimulation without () or with () IGF-I (50 ng/ml) for 10 min. Cell lysates were immunoprecipitated with an anti-vimentin (F and I) or anti-Ser(P) (G) or
anti-SHPS-1 (H) antibody and immunoblotted with an anti-PKC (F and H) or anti-vimentin (G) or anti-RPTP antibody (I). To control for loading, the same
amount of lysate was immunoblotted with an anti-PKC (F and H) or an anti-vimentin antibody (G and I). The mean value of the scanning units for ILK-associated
PKC divided by PKC (A), vimentin-associated PKC divided by PKC (B and F), serine-phosphorylated vimentin divided by vimentin (C), SHPS-1-associated
PKC divided by PKC (H), and vimentin-associated RPTP divided by vimentin (I). *, p  0.05; **, p  0.01; and ***, p  0.001, indicate significant differences
between two treatments. P, NS no significant difference.
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teins resulted in failure of IGFBP-2/IGF-I to stimulate RPTP
polymerization. That both IGFBP-2 and IGF-I were required
was shown by utilizing cells in which IGFBP-2 had been
knocked down to demonstrate that although IGF-I stimulated
vimentin serine phosphorylation, it could not stimulate vimen-
tin/RPTP association in the absence of IGFBP-2. Further-
more, addition of an IGF-I receptor tyrosine kinase inhibitor
resulted in failure of IGF-I to stimulate vimentin/RPTP asso-
ciation even in the presence of optimal concentrations of
IGFBP-2. Therefore, coordinate activation of both receptor sig-
naling systems is required for this interaction to occur.
Vimentin binding to RPTP was mediated by its serine phos-
phorylation. Exposure of cells to IGF-I resulted in an increase in
vimentin serine phosphorylation, and the serine/threonine
kinase that phosphorylates vimentin was shown to be PKC.
Inhibition of PKC activation resulted in complete attenuation
of vimentin-stimulated RPTP polymerization. More impor-
tantly, a synthetic peptide that contained the sequence from the
FIGURE 8. Disruption of vimentin/RPTP association impaired IGF-I-stimulated PTEN tyrosine phosphorylation and pAKT activation in vivo. A control
peptide (CP) or a disrupting peptide (AP) (A, C, and D) or a PKC inhibitor (B) was injected (intraperitoneally) into the mice (n  6 for each group) 24 and 1 h before
sacrifice. IGF-I () or PBS () was injected (intraperitoneally) 15 min before sacrifice. A, aortic extracts prepared as described under “Experimental Procedures”
were immunoprecipitated (IP) using an anti-vimentin and immunoblotted (IB) using an RPTP antibody. The same amount of extract was immunoblotted
using an anti-vimentin antibody. Each bar is the ratio of the mean value of the scanning units for vimentin-associated RPTP divided by vimentin. B, aortic
extracts were immunoprecipitated using an anti-Ser(P) (pSer) antibody and immunoblotted using an anti-vimentin antibody. The extracts were immuno-
blotted using an anti--actin antibody to control for a protein input. Each bar is the ratio of the mean value of the scanning units for serine phosphate vimentin
divided by -actin. C, aortic extracts from diabetic (DM, n  4) or nondiabetic mice (NM, n  4) that had been injected with IGF-I () (1 mg/kg, 15 min before
sacrifice) or PBS () were immunoprecipitated with an anti-Ser(P) antibody and immunoblotted with anti-vimentin antibody. For a loading control, the same
amount of aortic extract was immunoblotted with an anti-vimentin antibody. D, aortic extracts were immunoprecipitated using an anti-pY99 antibody and
immunoblotted using an anti-PTEN antibody. Each bar is the ratio of the mean value of the scanning units for pPTEN divided by PTEN. E, aortic extracts were
immunoblotted using an anti-pAKT(S473) antibody. The blots were stripped and reprobed with an anti--actin antibody. Each bar is the ratio of the scanning
units for pAKT divided by -actin. *, p  0.05, and **, p  0.01, indicate significant differences between two treatments.
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vimentin head domain that contained a consensus PKC phos-
phorylation site disrupted vimentin/RPTP binding, RPTP
polymerization, PTEN tyrosine phosphorylation, and AKT
activation. Therefore, these results definitively show that IGF-
I-stimulated serine phosphorylation of the head domain of
vimentin leads to RPTP polymerization. Blocking the vimen-
tin/RPTP interaction in mice utilizing the disrupting peptide
showed that it was required for RPTP polymerization and
AKT activation. Therefore, we conclude this is the mechanism
by which IGF-I and IGFBP-2 function to modulate the AKT
activation in vivo. Our prior studies have shown that optimal
activation of AKT in VSMC in response to IGF-I requires the
presence of hyperglycemia and that in cells maintained in 5 mM
glucose or in nondiabetic mouse aorta, IGF-I-stimulated AKT
activation (9, 20) and ki67 labeling are attenuated (16, 17). This
is due in part to reduced SHPS-1 phosphorylation (19) which
results in a decrease in PKC recruitment and activation (17).
The findings in this study are consistent with these results,
showing that in the presence of normal glucose, IGF-I-stimu-
lated vimentin serine phosphorylation and vimentin/RPTP
association were decreased. We conclude that hyperglycemia is
required for PKC activation and IGF-I-stimulated PKC
recruitment to the SHPS-1 signaling complex. PKC phosphor-
ylates vimentin, which then binds to RPTP. This association
resulted in enhanced downstream signaling and biological
responses.
The molecular mechanism by which vimentin was shown to
interact with RPTP was through serine phosphorylation of the
head domain. This domain, which encompasses the first 74
amino acids of the vimentin N terminus, contains multiple ser-
ine phosphorylation sites (21). A consensus sequence motif that
is a known PKC phosphorylation site is encompassed by resi-
dues 2–11. Proteins containing this sequence motif are prefer-
entially serine-phosphorylated by this kinase (22). Our studies
confirmed the importance of this domain by showing that a
peptide containing this sequence could completely disrupt
vimentin/RPTP association thereby inhibiting RPTP poly-
merization and downstream signaling in vitro and in vivo. Con-
firmation that PKC-phosphorylated vimentin was established
by using a specific PKC pseudosubstrate inhibitor and show-
ing that it inhibited IGF-I stimulated vimentin serine phosphor-
ylation as well as vimentin binding to RPTP. Other protein
kinases have been shown to phosphorylate the head domain of
vimentin including CAM kinase II, an important regulator of
smooth muscle cell proliferation (23). In addition, IGF-I has
been shown to induce CAM kinase II activation under certain
circumstances (24). However, IGF-I also induces protein kinase
C activation (25); therefore, taken together with the observa-
tion that a specific PKC inhibitor attenuated vimentin phos-
phorylation, we conclude that PKC is the kinase that phosphor-
ylates vimentin and that it is activated by IGF-I receptor
stimulation. Our observation that a peptide containing the
PKC phosphorylation site inhibited vimentin binding to
RPTP and RPTP polymerization suggests that this is the
region of vimentin that is phosphorylated and that it interacts
with RPTP to stimulate polymerization.
Serine phosphorylation of the vimentin head domain has
been shown to lead to multiple protein/protein interactions
and changes in target protein function (26). Tzivion et al. (27)
demonstrated that phosphorylation of vimentin sequestered
14-3-3 and that this resulted in differential binding of signaling
proteins, such as Raf, to vimentin thereby altering cellular sig-
naling. Similarly phosphorylation of serine 56 by PAK-1 kinase
was shown to alter p47 phox association with vimentin thereby
regulating smooth muscle cell contraction (28, 29). Vimentin
phosphorylation in smooth muscle has also been shown to reg-
ulate Crk-associated substrate association as well was translo-
cation of Rho kinase (28). Phosphorylation of serines in the
head domain regulates intermediate filament assembly and dis-
assembly in smooth muscle cells, and this results in differential
protein/protein interactions (18). This reassembly of interme-
diary filaments is thought to be an important regulator of cell
migration (30). Phosphorylation of vimentin has also been
shown to correlate with formation of glomerular lamellipodia,
which is essential for migration (26).
Disruption of vimentin/RPTP association had effects on
RPTP polymerization and downstream signaling events that
were similar to those observed following vimentin knockdown.
The mechanism by which vimentin and IGFBP-2 binding to
RPTP coordinately regulate RPTP polymerization has not
been determined. The proposed mechanism of RPTP poly-
merization has been thought to be due to solely ligand occu-
pancy of the extracellular domain because the binding of
ligands such as pleiotropin and midkine facilitates RPTP poly-
merization, presumably in the absence of concomitant binding
of intracellular proteins (31). It is clear from our studies that
IGFBP-2 association with RPTP alone is not sufficient to stim-
ulate polymerization, and vimentin binding to the RPTP cyto-
plasmic domain is required. RPTP polymerization is thought
to occur through formation of a wedge between catalytic
domains in the dimer and that wedge formation effectively
blocks substrate availability thereby inhibiting tyrosine dephos-
phorylation (32). The mechanism by which serine phosphory-
lation of vimentin would facilitate this interaction has not been
defined.
Because regulation of PKC subcellular localization has been
shown to be an important regulatory variable for determining
substrate specificity, we analyzed factors that might result in
differential PKC subcellular localization in response to IGF-I
stimulation. In smooth muscle cells exposed to hyperglycemia,
the primary target of the IGF-I receptor kinase is SHPS-1;
therefore, we examined proteins that were differentially
recruited to SHPS-1 phosphotyrosines (15). Our proteome-
wide screening studies had shown that ILK is recruited to the
SHPS-1 signaling complex in response to IGF-I. ILK is a pseudo-
kinase and does not have catalytic activity; therefore, it was
not a good candidate for directly phosphorylating vimentin
(33). However, ILK has been shown to be important for the
recruitment and subcellular localization of signaling molecules
(34). ILK forms a complex with two other proteins, PINCH and
parvin, that recruit a variety of signaling intermediates to this
complex (35). To determine whether ILK mediated PKC
recruitment, we utilized an ILK inhibitor that regulates protein
recruitment to the PINCH-parvin-ILK complex (35–37). Addi-
tion of the ILK inhibitor resulted in inhibition of IGF-I-stimu-
lated ILK/PKC association as well as vimentin phosphoryla-
Vimentin/RPTP Interaction Mediates IGF-I Signaling
11588 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 18 • MAY 1, 2015
tion leading to loss of vimentin/RPTP association. The
importance of IGF-I stimulated recruitment of ILK to SHPS-1
was validated by showing that cells expressing the SHPS-1 cyto-
plasmic domain-truncated mutant failed to recruit PKC to
vimentin. Therefore, we conclude that IGF-I-stimulated phos-
phorylation of SHPS-1 is required to recruit ILK-1 and that ILK
or the ILK-PINCH-parvin complex recruits PKC, thereby
facilitating PKC/vimentin interaction.
Several studies have demonstrated that assembly of the
PINCH-parvin-ILK complex is important for subcellular local-
ization of signaling molecules (35, 38). Rho kinase, MAPK, pax-
illin, NCK-2, PP-1, and 1 integrins are all recruited to this
complex under various conditions (38, 39). During stimulation
of cell migration, ILK interacts with multiple integrin receptors,
principally the -1 integrin, and recruitment of ILK to 1 in
focal adhesions is thought to play an important role in this
process (40). The ability of ILK to recruit specific signaling
components to focal adhesions has been proposed as an impor-
tant growth regulator mechanism (35). Overexpression of ILK
has been shown to regulate smooth muscle cell differentiation
(41), and the state of differentiation is an important component
of maintenance of signaling through the SHPS-1/PI 3-kinase
pathway, which is necessary for IGF-I-stimulated migration
(17). Our results are consistent with this model because they
show that ILK recruitment of PKC results in an enhancement
of IGF-I-stimulated AKT activation in VSMC, which is impor-
tant for optimal IGF-I-stimulated cell migration.
In summary, these studies have determined the mechanism
by which IGF-I receptor stimulation collaborates with IGFBP-2
binding to RPTP to lead to enhancement of AKT pathway-de-
pendent functions in vascular smooth muscle cells. IGF-I
receptor stimulation is required for activation of PKC-stimu-
lated vimentin serine phosphorylation, and this results in direct
binding of vimentin to RPTP, which facilitates IGFBP-2-me-
diated RPTP polymerization (Fig. 9). These results emphasize
the importance of collaborative signaling between the two
receptor systems to obtain optimal IGF-I responsiveness and
how these signaling pathways may be altered in diabetes. The
findings clearly emphasize the need for analysis of similar inter-
actions occurring between other IGF-binding proteins and
their respective receptors and the role of these interactions
mediating specific cellular functional responses following IGF-I
stimulation.
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